El interés en corto de Rigel Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Rigel Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa, Informe de interés en corto

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

WIIM

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVR

BNOX

FTRE

MRVI

NOTV

PRPH

RVNC

TIVC

12 Health Care Stocks Moving In Friday's Intraday Session

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.03 by 2233.33 percent. The company reported quarterly sales of $55.307 million which beat the analyst consensus estimate of $41.927 million by 31.91 percent. This is a 96.58 percent increase over sales of $28.134 million the same period last year.

Earnings

Earnings Beats

News

Rigel Pharmaceuticals Q3 2024 GAAP EPS $0.70 Beats $0.03 Estimate, Sales $55.307M Beat $41.927M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO&#xAE; (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The DHCP letter has been posted to the GAVRETO Healthcare Provider website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4286741-1&amp;h=3852763292&amp;u=https%3A%2F%2Fgavreto-hcp.com%2F&amp;a=www.gavreto-hcp.com">www.gavreto-hcp.com</a>.

Biotech

General

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For GAVRETO After Consultation With The U.S. FDA  For The Treatment Of Adult Patients With Metastatic Rearranged During Transfection

Optime Care Expands Partnership With Rigel Pharmaceuticals To Include Commercial Distribution Of TAVALISSE For Managing Chronic Immune Thrombocytopenia

Cantor Fitzgerald analyst Kristen Kluska reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and maintains $15 price target.

Cantor Fitzgerald Reiterates Neutral on Rigel Pharmaceuticals, Maintains $15 Price Target

Rigel Says First Patient Enrolled In Phase 1b/2 Triplet Therapy Trial Of Decitabine And Venetoclax In Combination With REZLIDHIA

<ul>
<li>Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea&nbsp;and Taiwan</li>
<li>Rigel will receive&nbsp;an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments</li>
<li>Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize REZLIDHIA&#xAE; (olutasidenib)&nbsp;in all current and potential indications in Japan, the Republic of Korea (Korea) and Taiwan. REZLIDHIA is commercially available to patients in the U.S. for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). Rigel has an existing agreement with Kissei to develop and commercialize TAVALISSE&#xAE; (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP) and in all other potential indications in Japan, China, Taiwan and the Republic of Korea.

Global

Rigel Expands Relationship With Kissei To include REZLIDHIA In Japan, The Republic Of Korea And Taiwan; Will Receive An Upfront Cash Payment Of $10M With The Potential For Up To $152.5M In Future Development, Regulatory, And Commercial Milestone Payments

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy with 1-for-10 Reverse Stock Split.

CORRECTION: HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals (1-for-10 Reverse Stock Split) - Headline Earlier Published on 9th Aug

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.31) by 80.65 percent. The company reported quarterly sales of $36.841 million which beat the analyst consensus estimate of $33.419 million by 10.24 percent. This is a 37.03 percent increase over sales of $26.886 million the same period last year.

Rigel Pharmaceuticals Q2 2024 GAAP EPS $(0.06) Beats $(0.31) Estimate, Sales $36.841M Beat $33.419M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol (RIGL) when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.
The Reverse Stock Split was approved by the company's stockholders at its Annual Meeting of Stockholders held on May 24, 2024 to be effected by the company's Board of Directors (the "Board") within approved parameters. The final ratio was approved by the Board on June 15, 2024. As a result of the Reverse Stock Split, every 10 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. This will reduce the number of shares outstanding from approximately 175,582,945 shares to approximately 17,558,294, subject to adjustment due to the payment of cash in lieu of fractional shares. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the company's equity plans, as applicable. The Reverse Stock Split will not affect the number of authorized shares of common stock or the par value of the common stock.

Stock Split

Rigel Announces 1-For-10 Reverse Stock Split, Will Begin Trading On A Post-Split Basis When The Market Opens On Thursday, June 27, 2024

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $15 price target.

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024
SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO&#xAE; (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). GAVRETO will be commercially available from Rigel in the U.S. by prescription beginning June 27, 2024.

Rigel Pharmaceuticals Completes Transfer Of GAVRETO New Drug Application; Will Be Available In The U.S. Beginning June 27, 2024

Rigel Pharmaceuticals: Looking For More Growth

Rigel Pharmaceuticals (RIGL) is issuing a Dear Health Care Provider – DHCP – letter related to a new safety signal for Gavreto – pralsetinib – afte...

Rigel Pharmaceuticals issues Dear Healthcare Provider letter for Gavreto

Rigel issues letter to doctors on fatal infection signal for Gavreto

Here are the major earnings after the close today

Rigel Pharmaceuticals GAAP EPS of $0.70 beats by $0.63, revenue of $55.3M beats by $13.37M

Rigel Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Rigel Pharmaceuticals ( ($RIGL) ) has released its Q3 earnings. Here is a breakdown of the information Rigel Pharmaceuticals presented to its inves...

Rigel Pharmaceuticals Reports Strong Q3 2024 Results

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel (RIGL – Research Report) today and set a price target of $57.00. Joseph P...

Rigel's Robust Financial Performance and Strategic Partnerships Drive Buy Rating

Rigel stock rallies 36% after Q3 earnings beat

AAOI

AAON

ACHR

ACHV

ADMA

ADPT

AEYE

AFRM

AKAM

ALLO

ALRM

ALTM

AMPL

AMRC

ANET

ARCT

ARLO

ARRY

ASLE

DOCS

DVAX

FIVN

FNKO

FOSL

GSBD

GTBIF

HASI

HEAR

INDI

INGN

NWSA

OPEN

OUST

PACB

PARA

PBPB

PBYI

PHUN

PINS

PODD

PRCH

PTCT

PTMN

QDEL

RCEL

RCMT

RDFN

REZI

RIVN

SAND

SEMR

SENS

SIGA

Press Releases

Rigel to Participate in Upcoming September Investor Conferences

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Health Care

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Comments

Rigel Pharmaceuticals

Interés en corto

Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL